Piper Sandler Reiterates Overweight Rating on OPKO Health (NASDAQ:OPK)

OPKO Health (NASDAQ:OPK – Get a Free Report)The “overweight” rating on its stock was reiterated by equity researchers at Piper Sandler in a report on Tuesday, Benzinga reports. They currently have a $3.00 target price on the biotechnology company’s stock. Piper Sandler’s price objective would suggest a potential upside of 85.19% from the stock’s current price.

Other equities research analysts have recently issued research reports on the stock. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Barrington Research upped their target price on OPKO Health from $1.50 to $2.25 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Tuesday.

Check out our latest report on OPK

OPKO health price performance

Shares of NASDAQ:OPK opened at $1.62 on Tuesday. The firm has a market cap of $1.13 billion, a PE ratio of -4.63 and a beta of 1.64. The company has a current ratio of 1.63, a quick ratio of 1.36, and a debt-to-equity ratio of 0.13. OPKO Health has a 1 year low of $0.85 and a 1 year high of $1.75. The company’s 50-day moving average is $1.51 and its 200-day moving average is $1.32.

OPKO Health (NASDAQ:OPK – Get Your Free Report ) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.08. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The business had revenue of $182.20 million for the quarter, compared to analyst estimates of $184.70 million. During the same period in the previous year, the business earned EPS of ($0.03). The company’s revenue fell 31.3% year over year. sell-side analysts forecast that OPKO Health will post -0.29 earnings per share for the current year.

Insider buying and selling

In related news, major shareholder Opko Health, Inc. sold 12,994 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $29.35, for a total value of $381,373.90. Following the sale, the insider now directly owns 2,971,570 shares of the company’s stock, valued at approximately $87,215,579.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 736,644 shares of company stock worth $23,874,134. 47.26% of the shares are owned by company insiders.

Institutional trading of OPKO Health

A number of institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP grew its position in OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after purchasing an additional 39,486,490 shares during the last quarter. YD More Investments Ltd bought a new stake in OPKO Health in the second quarter valued at approximately $1,840,000. Squarepoint Ops LLC bought a new stake in OPKO Health in the second quarter valued at about $592,000. Lazard Asset Management LLC purchased a new position in OPKO Health in the first quarter valued at about $258,000. Finally, BNP Paribas Financial Markets raised its stake in OPKO Health by 349.8% in the fourth quarter. BNP Paribas Financial Markets now owns 271,872 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 211,429 shares in the last quarter. Institutional investors own 64.63% of the company’s shares.

OPKO Health company profile

(Get a free report)

OPKO Health, Inc, a healthcare company, engages in diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico and internationally. The company’s Diagnostics segment operates BioReference Laboratories which provides laboratory testing services for the detection, diagnosis, evaluation, monitoring and treatment of diseases, including esoteric testing, molecular diagnostics, anatomic pathology, genetics, women’s health and correctional healthcare to medical offices, clinics. , hospitals, employers and government units; and the 4Kscore test for prostate cancer.

See Also

Get news and reviews for OPKO Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OPKO Health and related companies with MarketBeat.com ‘s FREE daily email newsletter.